Overview

A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)

Status:
Completed
Trial end date:
2019-09-09
Target enrollment:
Participant gender:
Summary
This is a Phase IIa, open-label, randomized study in treatment-naïve, sputum smear-positive patients with drug-sensitive pulmonary TB to assess the early bactericidal activity of telacebec (Q203).
Phase:
Phase 2
Details
Lead Sponsor:
Qurient Co., Ltd.